Search - tctmd.com

Displaying 721 - 740 of 1993

Sort: Relevancy | Date

News Daily News

Ticagrelor Monotherapy After Multivessel PCI? Latest Slice From GLOBAL LEADERS Says . . . Maybe

Yael L. Maxwell

October 16, 2019

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

Todd Neale

October 14, 2019

News Daily News

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Shelley Wood

October 14, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Michael O'Riordan

October 09, 2019

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Todd Neale

October 03, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Todd Neale

September 30, 2019

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Caitlin E. Cox

September 20, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Yael L. Maxwell

September 03, 2019

Advertisement

Ticagrelor Monotherapy After Multivessel PCI? Latest Slice From GLOBAL LEADERS Says . . . Maybe

FDA Gives Rivaroxaban Another VTE-Related Indication

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Recurrent Events Common Among Young Patients With CAD

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

TCTMD’s Top 10 Most Popular Stories for September 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content